Recently, we characterized the super-enhancer landscape of ACC and closely matched these cell lines with patient samples and clinically relevant ACC cluster types C1A (SF-1-high, steroidogenic-high/TVBF-7 and NCI-H295R) and C1B (SF-1, steroidogenic-low/MUC-1). This evidence concerns the gene MUC1 and adrenal cortex carcinoma.